| 11.51 -1.16 (-9.16%) | 01-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 15.41 | 1-year : | 17.36 |
| Resists | First : | 13.19 | Second : | 14.86 |
| Pivot price | 12.26 |
|||
| Supports | First : | 10.49 | Second : | 8.72 |
| MAs | MA(5) : | 12.55 |
MA(20) : | 12.19 |
| MA(100) : | 11.64  |
MA(250) : | 11.07 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 48 |
D(3) : | 59.6 |
| RSI | RSI(14): 43.7 |
|||
| 52-week | High : | 14.86 | Low : | 8.5 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BBOT ] has closed above bottom band by 14.5%. Bollinger Bands are 7.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 12.8 - 12.87 | 12.87 - 12.93 |
| Low: | 11 - 11.09 | 11.09 - 11.16 |
| Close: | 11.39 - 11.53 | 11.53 - 11.63 |
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI3K pathways. The company recently went public through a business combination with Helix Acquisition Corp. II, raising approximately $450 million to advance clinical development. The CEO is Dr. Eli Wallace, and the CSO is Dr. Pedro Beltran.
Tue, 13 Jan 2026
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Mon, 12 Jan 2026
BBOT: Robust efficacy and safety data position these assets as leaders in KRAS-targeted cancer therapy - TradingView — Track All Markets
Fri, 09 Jan 2026
Raymond James Initiates Coverage of BridgeBio Oncology Therapeutics (BBOT) with Outperform Recommendation - Nasdaq
Sun, 21 Dec 2025
BridgeBio Oncology Therapeutics, Inc.(NasdaqGM: BBOT) added to S&P Global BMI Index - marketscreener.com
Mon, 15 Dec 2025
Assessing BridgeBio Oncology Therapeutics (BBOT) Valuation After Recent Share Price Pullback - Yahoo Finance
Fri, 12 Dec 2025
BridgeBio Oncology Therapeutics: Promising KRAS Drug Developer - In My View, At Least - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 80 (M) |
| Shares Float | 31 (M) |
| Held by Insiders | 27 (%) |
| Held by Institutions | 68 (%) |
| Shares Short | 1,130 (K) |
| Shares Short P.Month | 977 (K) |
| EPS | -1.46 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.63 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.56 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -87 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -7.94 |
| PEG Ratio | 0 |
| Price to Book value | 2.04 |
| Price to Sales | 0 |
| Price to Cash Flow | -10.63 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|